Cidara Therapeutics (CDTX) CMO Resigns fro Another Position
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced that the company has named Taylor Sandison, M.D., M.P.H., its vice president, clinical development, to the position of acting chief medical officer, effective September 2, 2016. Dr. Sandison will replace Dirk Thye, M.D., Cidara’s previous chief medical officer, who has accepted a CEO position at a non-competing San Francisco Bay Area-based biotech company. Dr. Thye will continue to assist Cidara as a consultant.
“We wish Dirk all the best as he pursues his new endeavor, and we extend our sincere gratitude for his exceptional work in spearheading our antifungal development programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We are pleased to have a highly experienced internal replacement in Taylor, allowing for a seamless transition of responsibilities. Taylor’s extensive experience has already been extremely valuable to our progress.”
Dr. Sandison has been with Cidara since October 2015. Prior to joining the company, he served as senior medical director at Cubist Pharmaceuticals, Inc. from July 2014 to January 2015 and then, following Merck’s acquisition of Cubist, as senior medical director at Merck from February to October 2015. Dr. Sandison has also held positions at Trius Therapeutics and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, and M.D. and M.P.H. degrees from the University of Washington. He completed residency training at the University of Colorado and fellowship training at the University of Washington. Dr. Sandison holds board certifications in Infectious Diseases and Internal Medicine.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Diplomat Pharmacy (DPLO) CFO Sean Whelan to Step Down; Paul Urick Promoted to President
- Huntington Bancshares (HBAN) Tops Q3 EPS by 1c
- A.O. Smith (AOS) Tops Q3 EPS by 2c; Guides In-Line
Create E-mail Alert Related CategoriesManagement Changes, Management Comments
Related EntitiesStanford, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!